Protocol to isolate quiescent hepatic stellate cells in sufficient yield while maintaining cytokine responsiveness from aged female mice Authors: Takao Seki, Sachiko Komazawa-Sakon, Yuichi Tsuchiya, Kyoko Fukuhara, Yasuhiro Nakano, Kenichi Ikejima, Katsuhide Okunishi, Hiroyasu Nakano Published: 2025 ABSTRACT SummaryIsolation of primary hepatic stellate cells (HSCs) in sufficient quantities is technically challenging. We present a protocol for isolating quiescent HSCs from mice using Nycodenz density-gradient centrifugation. The procedure includes cervical dislocation, vena cava cannulation, liver perfusion, enzymatic digestion, and preparation for density separation. We then describe centrifugation, enrichment, washing, counting, and culture preparation. This protocol provides fresh HSCs suitable for diverse experimental applications.For complete details on the use and execution of this protocol, please refer to Seki et al.1Subject areas: Cell biology, Cell culture, Cell isolation, Cell separation/fractionation, Model organisms, Stem cells Before you begin Hepatic stellate cells (HSCs) are the major storage site for vitamin A and play a central role in maintaining vitamin A homeostasis under physiological conditions.2,3 Following liver injury, however, HSCs become activated and transdifferentiate into myofibroblasts, which produce large amounts of extracellular matrix and thereby drive liver fibrosis. To elucidate the mechanisms by which cytokines and mechanical cues activate HSCs, it is essential to obtain sufficient numbers of cells in their quiescent state. In practice, reproducibly isolating adequate quantities of fresh quiescent HSCs from murine livers is technically challenging. Consequently, immortalized human or mouse HSC lines are often used to study cytokine responsiveness and signaling pathways.4 However, there are many discrepancies between primary quiescent HSCs and immortalized lines, underscoring the need for robust methods to isolate fresh HSCs for physiologically relevant analyses. Innovation This protocol provides a reproducible and relatively straightforward method for isolating quiescent hepatic stellate cells (HSCs) from murine livers. It builds on established procedures that combine pronase/collagenase digestion with Nycodenz density-gradient centrifugation, while incorporating several key optimizations. These include the use of aged female mice, cervical dislocation, vena cava cannulation, liver perfusion, enzymatic digestion, and refined preparation for density-gradient separation. Together, these improvements markedly enhance cell yield while reliably preserving the responsiveness of isolated HSCs to profibrotic cytokines. This refined protocol thus offers a valuable platform for fibrosis research, narrowing the gap between in vitro studies using immortalized HSC lines and analyses that more accurately reflect the physiological behavior of primary HSCs. Institutional permissions (if applicable) All animal experiments should be conducted in strict accordance with relevant institutional and national guidelines and regulations. Appropriate approval from the institutional animal care and use committee must be obtained prior to initiating this protocol. Mouse preparation and housing Timing: 7–14 days 1.Obtain female C57BL/6 mice aged ≧24 weeks (average body weight: 25-30 g). Obtain female C57BL/6 mice aged ≧24 weeks (average body weight: 25-30 g). Note: A typical yield is 0.5 × 106 to 1.0 × 106 viable HSCs per mouse, with a purity of 80–90%. CRITICAL: Use only aged female mice. Aged male mice exhibit markedly reduced HSC isolation efficiency and purity due to lipid accumulation in hepatocytes, which interferes with density-gradient separation and compromises HSC yield (data not shown). Retired breeder females are a cost-effective choice for this protocol, as they meet the age requirement (≥24 weeks) and are typically available at a lower cost than younger, purpose-bred mice aged 8–12 weeks. Buffer and equipment preparation Timing: 1–2 h 2.Prepare all buffer solutions according to the recipes in the materials and equipment section. Prepare all buffer solutions according to the recipes in the materials and equipment section. Note: Filter all solutions through 0.22-μm filters to ensure sterility. 3.Pre-warm LPM1, LPM2, and digestion buffers 1–3 to 37 °C in 50-mL Falcon tubes. Pre-warm LPM1, LPM2, and digestion buffers 1–3 to 37 °C in 50-mL Falcon tubes. CRITICAL: Maintain enzyme solutions at 37°C to ensure optimal activity. Using cold solutions will markedly reduce digestion efficiency. 4.Sterilize peristaltic pump tubing by running 70% ethanol through the system for 2–3 min (Figure 1A). Sterilize peristaltic pump tubing by running 70% ethanol through the system for 2–3 min (Figure 1A). 5.Set up the surgical area using an aluminum foil–covered styrofoam board (Figure 1B). Set up the surgical area using an aluminum foil–covered styrofoam board (Figure 1B). CRITICAL: Position the surgical setup close to the peristaltic pump to minimize tubing length and maintain a consistent flow rate. 6.Prepare the mesh filtration system by securing mesh stockings over collection funnels (Figure 1C).a.Spray funnels and mesh stockings with 70% ethanol.b.Place them in a clean bench and expose to UV irradiation for 30 min. Prepare the mesh filtration system by securing mesh stockings over collection funnels (Figure 1C).a.Spray funnels and mesh stockings with 70% ethanol.b.Place them in a clean bench and expose to UV irradiation for 30 min. a.Spray funnels and mesh stockings with 70% ethanol. Spray funnels and mesh stockings with 70% ethanol. b.Place them in a clean bench and expose to UV irradiation for 30 min. Place them in a clean bench and expose to UV irradiation for 30 min. Note: Commercial mesh stockings or 70-μm cell strainers can be used for filtration. Mesh stockings offer cost-effectiveness and reduced clogging due to their elasticity, while cell strainers provide standardized pore size. Proper sterilization is essential to avoid contamination during cell filtration. Equipment preparation, surgical procedure, and liver perfusion (A) Experimental setup showing a peristaltic pump and perfusion buffers pre-warmed to 37 °C. Arrange LMP1, Digestion Buffer 1 (DB1), and Digestion Buffer 2 (DB2) side by side to facilitate seamless sequential replacement of the perfusion solution. (B) Surgical area prepared with an aluminum foil–covered polystyrene foam board for the liver perfusion procedure. (C) Cost-effective mesh filtration system prepared using commercial stockings placed over collection funnels. Created in BioRender. Seki, T. (2025) https://BioRender.com/nwby1b8. (D) Exposure of the portal vein and inferior vena cava after laparotomy. (E) Insertion and fixation of a 25G winged needle with a disposable clip for retrograde perfusion via the inferior vena cava. (F) Color change of the liver indicating successful blood removal and initiation of perfusion. (G) Incision of the portal vein for drainage to maintain proper perfusion flow. (H) Appearance of a partially digested liver following sequential enzymatic perfusion. Nycodenz gradient preparation Timing: 30 min 7.Prepare a 30% Nycodenz solution in GBSS/B buffer. Prepare a 30% Nycodenz solution in GBSS/B buffer. Note: A 30% Nycodenz stock solution can be prepared in advance and stored at 4°C for up to 6 months without loss of activity. 8.Calculate the required volumes. For two mice, prepare 20 mL of 8.8% Nycodenz working solution (10 mL per mouse) immediately before use by diluting the 30% stock with GBSS/B. Calculate the required volumes. For two mice, prepare 20 mL of 8.8% Nycodenz working solution (10 mL per mouse) immediately before use by diluting the 30% stock with GBSS/B. CRITICAL: The 8.8% Nycodenz working solution must be freshly prepared during the procedure. This concentration has been optimized for HSC separation based on their specific density characteristics. Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-desmin rabbit monoclonal antibody (working dilution at 1:100)AbcamCat#AB32362; RRID: AB_731901Anti-αSMA rabbit monoclonal antibody (working dilution at 1:100)AbcamCat#AB124964; RRID: AB_11129103Alexa 647-conjugated donkey anti-rabbit IgG (working dilution at 1:500)InvitrogenCat#A31573; RRID: AB_2536183Bacterial and virus strainspPS-EF1-SV40 large T antigenSeki et al.1N/ApPS-EF1-LCS-T2A-RFPSystem BioscienceCat#LF520A-1Chemicals, peptides, and recombinant proteinsIsofluraneWakoCat#099-06571Sodium chloride (NaCl)WakoCat#191-01665Potassium chloride (KCl)Kanto ChemicalCat#32326-00Magnesium chloride hexahydrate (MgCl2·6H2O)Nacalai TesqueCat#20909-55Magnesium sulfate heptahydrate (MgSO4·7H2O)WakoCat#131-00405Potassium dihydrogenphosphate (KH2PO4)WakoCat#169-04245Disodium hydrogenphosphate 12-Water (Na2HPO4·12H2O)Nacalai TesqueCat#31723-64Sodium dihydrogenphosphate dihydrate (NaH2PO4·2H2O)WakoCat#192-02815D(+)-glucoseKanto ChemicalCat#10017-00Sodium bicarbonate (NaHCO3)Kanto ChemicalCat#37116-00Calcium chloride dihydrate (CaCl2·2H2O)WakoCat#031-00435EGTANacalai TesqueCat#15214-92HEPESSigmaCat#H4034-500GCollagenase type IVSigma-AldrichCat#C5138DNase ISigma-AldrichCat#DN25NycodenzSEWCat#18003Actinase E (Pronase E)KNFCat#KA-002Human FGF18PeproTechCat#100-28Human TGF-β1PeproTechCat#100-21Fetal bovine serumGibcoCat#10270106High glucose DMEMNacalai TesqueCat#16971-55Benzylpenicillin potassiumMeiji-seika-pharmaCAS: 113-98-4Kanamycin sulfateWakoCat#113-00343Vancomycin hydrochlorideWakoCat#226-01306Gentamycin sulfateWakoCat#079-02973Streptomycin sulfateMeiji-seika-pharmaCAS: 3810-74-0Normal donkey serumJackson ImmunoResearchCat#017-000-12110%-formaldehyde neutral buffer solutionNacalai TesqueCat#37152-51Citrate buffer solutionLSI MedicineCat#RM-102CVectashield mounting medium with DAPIVectorCat#H-1200Sepasol-RNA I SuperGNacalai TesqueCat#09379-55Critical commercial assaysRNeasy Micro KitQIAGENCat#74004ReverTra Ace qPCR RT KitToyoboCat#FSQ-101Fast SYBR Green Master MixApplied BiosystemsCat#4385614Experimental models: Cell linesImmortalized mouse HSCs (iHSCs)Seki et al.1N/ALX-2 cell line (human HSCs)MerckCat#SCC064Experimental models: Organisms/strainsMouse: C57BL/6, female, ≥24 weeksCrea-JapanN/AOligonucleotides (mouse)Acta2 Fwd primer: 5′-CTGACAGAGGCACCACTGAA-3′Seki et al.1N/AActa2 Rev primer: 5′- CATCTCCAGAGTCCAGCACA-3′Seki et al.1N/ACol1a2 Fwd primer: 5′-CAGAACATCACCTACCACTGCAA-3′Seki et al.1N/ACol1a2 Rev primer: 5′-TTCAACATCGTTGGAACCCTG-3′Seki et al.1N/ACcnd1 Fwd primer: 5′-CAGAAGTGCGAAGAGGAGGTC-3′Seki et al.1N/ACcnd1 Rev primer: 5′-TCATCTTAGAGGCCACGAACAT-3′Seki et al.1N/ASpp1 Fwd primer: 5′-CACTCCAATCGTCCCTAC-3′Seki et al.1N/ASpp1 Rev primer: 5′-AGACTCACCGCTCTTCAT-3′Seki et al.1N/AHprt Fwd primer: 5′-AACAAAGTCTGGCCTGTATCCAA-3′Seki et al.1N/AHprt Rev primer: 5′-GCAGTACAGCCCCAAAATGG-3′Seki et al.1N/AOligonucleotides (human)ACTA2 Fwd primer: 5′-GTGTTGCCCCTGAAGAGCAT-3′This paperN/AACTA2 Rev primer: 5′- GCTGGGACATTGAAAGTCTCA-3′This paperN/ACOL1A2 Fwd primer: 5′-GTTGCTGCTTGCAGTAACCTT-3′This paperN/ACOL1A2 Rev primer: 5′-AGGGCCAAGTCCAACTCCTT-3′This paperN/ACCND1 Fwd primer: 5′-CCGAGGAGCTGCTGCAAAT-3′This paperN/ACCND1 Rev primer: 5′-GAAATCGTGCGGGGTCATTG-3′This paperN/ASPP1 Fwd primer: 5′-CAGACCTGACATCCAGTACCC-3′This paperN/ASPP1 Rev primer: 5′-GTGGGTTTCAGCACTCTGGT-3′This paperN/AGAPDH Fwd primer: 5′-TGCTTCCAGGTACAGGTGCT-3′This paperN/AGAPDH Rev primer: 5′-GCTGCTTACGGCTCACATCG-3′This paperN/ASoftware and algorithmsGraphPad Prism 10GraphPad Softwarehttps://www.graphpad.com/QuantStudio Design & Analysis Software v2.6Thermo Fisher Scientifichttps://www.thermofisher.com/OtherSteritop Vaccum Driven Disposable Filtration SystemMilliporeCat#SCGPS05RE25G winged infusion set (Sure Shield SV Set)TerumoCat#SV-S25ELDisposable clipNATSUMECat#KN-353-AM1-60Mesh filter (stockings)100 YEN SHOP WattsCat#LC0896-0370 μm Cell strainerAS ONECat#VCS-70Funnel100 YEN SHOP WattsCat#031495Peristaltic pumpIWAKIModel#PST-100Magnetic stirrerNISSINCat#SW-M120Magnetic stirrer barCowieCat#001.515Water bath (Thermo minder)TAITECModel#SM-OSN10 cm Petri dishGreiner Bio-OneCat#633181Sterile 25 mL serological pipettesThermo Fisher ScientificCat#170357NSterile 15 mL centrifuge tubesCorningCat#430791Sterile 50 mL centrifuge tubesSarstedtCat#62.547.254Culture Plate VTC-P48ViolamoCat#2-8588-04Culture Plate VTC-P12ViolamoCat#2-8588-0270% ethanolN/AN/ALOW SPEED REFRIGERATED CENTRIFUGETOMYModel#AX-521QuantStudio 3 Real-Time PCR SystemThermo Fisher ScientificModel#A28137Poly-L-lysine-coated 12 mm microcoverslipsMatsunamiCat#C012001All-in-One microscope (BZ-X700)KEYENCEModel#BZ-X700 Materials and equipment Liver Perfusion Medium1ReagentFinal concentrationAmountNaCl136 mM8 gKCl5.4 mM0.4 gEGTA0.5 mM0.18 gNaH2PO4·2H2O0.5 mM0.078 gNa2HPO4·12H2O0.42 mM0.151 gGlucose5 mM0.9 gNaHCO34.2 mM0.35 gHEPES10 mM2.38 gddH2ON/A1000 mLTotalN/A1000 mLDissolve these compounds in 950 mL of ddH2O while stirring. Adjust the pH to 7.4 with 10 N NaOH. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. Liver Perfusion Medium1 Dissolve these compounds in 950 mL of ddH2O while stirring. Adjust the pH to 7.4 with 10 N NaOH. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. Liver Perfusion Medium2ReagentFinal concentrationAmountNaCl136 mM8 gKCl5.4 mM0.4 gCaCl2·2H2O5 mM0.7416 gNaH2PO4·2H2O0.5 mM0.078 gNa2HPO4·12H2O0.42 mM0.151 gNaHCO34.2 mM0.35 gHEPES10 mM2.38 gddH2ON/A1000 mLTotalN/A1000 mLDissolve these compounds in 950 mL of ddH2O while stirring. Adjust the pH to 7.4 with 10 N NaOH. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. Liver Perfusion Medium2 Dissolve these compounds in 950 mL of ddH2O while stirring. Adjust the pH to 7.4 with 10 N NaOH. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. Digestion Buffer1ReagentFinal concentrationAmountActinase E (Pronase E)0.6 mg/ml30 mgLPM2N/A50 mLTotalN/A50 mLPrepare freshly before use. Make 25 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. Digestion Buffer1 Prepare freshly before use. Make 25 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. Digestion Buffer 2ReagentFinal concentrationAmountCollagenase0.3 mg/ml15 mgLPM2N/A50 mLTotalN/A50 mLPrepare freshly before use. Make 25 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. Digestion Buffer 2 Prepare freshly before use. Make 25 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. Digestion Buffer 3ReagentFinal concentrationAmountCollagenase0.6 mg/ml12 mgActinase E (pronase E)0.6 mg/ml12 mgLPM2N/A20 mLTotalN/A20 mLPrepare fresh before use. Make 10 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. Digestion Buffer 3 Prepare fresh before use. Make 10 mL per mouse. After preparation, maintain at 37°C in a water bath. Do not store. GBSS/B BufferReagentFinal concentrationAmountNaCl136 mM8 gKCl5.4 mM0.37 gMgCl2·6H2O1 mM0.21 gMgSO4·7H2O0.28 mM0.07 gKH2PO40.22 mM0.03 gNa2HPO4·12H2O0.42 mM0.151 gGlucose5.5 mM0.991 gNaHCO32.7 mM0.227 gCaCl2·2H2O1.5 mM0.225 gddH2ON/A1000 mLTotalN/A1000 mLDissolve these compounds in 950 mL of ddH2O while stirring. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. GBSS/B Buffer Dissolve these compounds in 950 mL of ddH2O while stirring. Bring volume to 1000 mL with ddH2O, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. 30% Nycodenz in GBSS/BReagentFinal concentrationAmountNycodenz30%60 gGBSS/BN/A200 mLTotalN/A200 mLDissolve Nycodenz in 120 mL of GBSS/B while stirring. Bring volume to 200 mL with GBSS/B, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. 30% Nycodenz in GBSS/B Dissolve Nycodenz in 120 mL of GBSS/B while stirring. Bring volume to 200 mL with GBSS/B, then filter through a 0.22 μm filter. Store at 4°C for up to 6 months. Step-by-step method details This protocol builds on established methods for hepatocyte and HSC isolation but incorporates critical optimizations to improve yield, purity, and reproducibility. Key improvements include: (1) a rapid transition from anesthesia to perfusion to minimize needle displacement, (2) cost-effective filtration using commercial mesh materials, (3) optimized gentle processing to prevent premature HSC activation, and (4) specific adjustments for aged female mice to enhance vitamin A–dependent density separation. CRITICAL: The perfusion and isolation steps (Steps 2-13) are adapted from established HSC isolation methods,5,6 with modifications in the enzymatic digestion process (Steps 12-13) designed to preserve both structural integrity and functional responsiveness. Parameters such as perfusion flow rate, enzyme concentrations, and timing have been optimized specifically to retain cytokine responsiveness.1,7 Mouse cervical dislocation and inferior vena cava cannulation Timing: 10 min This step establishes IVC access for liver perfusion using a rapid sequence of anesthesia, cervical dislocation, and immediate perfusion. This approach prevents needle displacement often observed with prolonged anesthesia protocols and ensures optimal perfusion efficiency. CRITICAL: Complete all preparatory steps before anesthetizing the mouse. The peristaltic pump must be pre-loaded with warm LPM1 and the 25G winged needle prepared for immediate insertion. 1.Pre-load the peristaltic pump with warm LPM1 (37 °C) and connect a 25G winged infusion set.a.Use tubing with 3 mm inner diameter and 5 mm outer diameter (Figure 1A).b.Set flow rate to 8.33 mL/min (dial setting 5).c.Prime the tubing completely to remove all air bubbles.d.Confirm smooth flow of LPM1 from the needle tip without air bubbles. Pre-load the peristaltic pump with warm LPM1 (37 °C) and connect a 25G winged infusion set.a.Use tubing with 3 mm inner diameter and 5 mm outer diameter (Figure 1A).b.Set flow rate to 8.33 mL/min (dial setting 5).c.Prime the tubing completely to remove all air bubbles.d.Confirm smooth flow of LPM1 from the needle tip without air bubbles. a.Use tubing with 3 mm inner diameter and 5 mm outer diameter (Figure 1A). Use tubing with 3 mm inner diameter and 5 mm outer diameter (Figure 1A). b.Set flow rate to 8.33 mL/min (dial setting 5). Set flow rate to 8.33 mL/min (dial setting 5). c.Prime the tubing completely to remove all air bubbles. Prime the tubing completely to remove all air bubbles. d.Confirm smooth flow of LPM1 from the needle tip without air bubbles. Confirm smooth flow of LPM1 from the needle tip without air bubbles. CRITICAL: Air bubbles can cause uneven perfusion and damage liver architecture. Complete removal is essential for successful HSC isolation. Note: Position the primed needle for immediate access. 2.Anesthetize the mouse with isoflurane following institutional guidelines. Anesthetize the mouse with isoflurane following institutional guidelines. Note: Minimize anesthesia duration to maintain optimal physiological conditions. 3.Perform cervical dislocation while the mouse remains under anesthesia. Perform cervical dislocation while the mouse remains under anesthesia. CRITICAL: This rapid sequence prevents needle displacement, which is common with prolonged anesthesia. Traditional multi-drug anesthesia mixtures may trigger reflexive movements that dislodge the cannula. 4.Spray the mouse with 70% ethanol, and a large incision is made in the abdominal wall to expose the internal organs (Figure 1D). Spray the mouse with 70% ethanol, and a large incision is made in the abdominal wall to expose the internal organs (Figure 1D). CRITICAL: Avoid damaging the liver or diaphragm, as this will compromise perfusion efficiency. Rapid execution is essential to preserve tissue viability. 5.Expose the portal vein and IVC by gently moving the intestines aside (Figure 1D). Expose the portal vein and IVC by gently moving the intestines aside (Figure 1D). Note: Use forceps carefully to avoid bleeding. 6.Insert the 25G winged needle into the IVC and start the peristaltic pump immediately (Figure 1E). Insert the 25G winged needle into the IVC and start the peristaltic pump immediately (Figure 1E). Note: Retrograde perfusion via the IVC is less technically demanding than portal vein cannulation and provides better reproducibility. 7.Confirm the color change of the liver from dark red to pale yellow, secure the needle with a disposable clip, and incise the portal vein for drainage (Figures 1F and 1G).a.Secure the needle position with a clip.b.Stabilize tubing by placing a weight (e.g., scissors) on it to prevent movement. Confirm the color change of the liver from dark red to pale yellow, secure the needle with a disposable clip, and incise the portal vein for drainage (Figures 1F and 1G).a.Secure the needle position with a clip.b.Stabilize tubing by placing a weight (e.g., scissors) on it to prevent movement. a.Secure the needle position with a clip. Secure the needle position with a clip. b.Stabilize tubing by placing a weight (e.g., scissors) on it to prevent movement. Stabilize tubing by placing a weight (e.g., scissors) on it to prevent movement. Note: The portal vein incision serves as an outlet for perfusate and ensures proper circulation through the liver vasculature. CRITICAL: Confirm proper drainage to prevent liver swelling and maintain consistent perfusion pressure. Sequential liver perfusion Timing: 15 min This step removes blood and circulating cells from the liver vasculature while chelating calcium to weaken cell–cell interactions. Sequential perfusion with LPM1, followed by Digestion Buffers 1 and 2, ensures optimal preparation for subsequent enzymatic digestion. 8.Perfuse with 25 mL LPM1 to remove blood from the liver (see troubleshooting 1). Perfuse with 25 mL LPM1 to remove blood from the liver (see troubleshooting 1). Note: Complete blood removal is indicated by the liver color being continuously a pale yellow-white color. 9.Switch to digestion buffer 1 (0.6 mg/mL Pronase E in LPM2) and perfuse 25 mL.a.Reduce flow rate to 6.66 mL/min (dial setting 4).b.Transfer the inlet tubing from LPM1 to the 50 mL tube containing digestion buffer 1.c.Avoid introducing air into the tubing system. Switch to digestion buffer 1 (0.6 mg/mL Pronase E in LPM2) and perfuse 25 mL.a.Reduce flow rate to 6.66 mL/min (dial setting 4).b.Transfer the inlet tubing from LPM1 to the 50 mL tube containing digestion buffer 1.c.Avoid introducing air into the tubing system. a.Reduce flow rate to 6.66 mL/min (dial setting 4). Reduce flow rate to 6.66 mL/min (dial setting 4). b.Transfer the inlet tubing from LPM1 to the 50 mL tube containing digestion buffer 1. Transfer the inlet tubing from LPM1 to the 50 mL tube containing digestion buffer 1. c.Avoid introducing air into the tubing system. Avoid introducing air into the tubing system. CRITICAL: Air bubbles can disrupt perfusion and damage liver architecture. Maintain continuous flow during buffer changes. 10.Switch to digestion buffer 2 (0.3 mg/mL Collagenase in LPM2) and perfuse 25 mL.a.Maintain flow rate at 6.66 mL/min (dial setting 4).b.Transfer the inlet tubing from digestion buffer 1 to the 50 mL tube containing digestion buffer 2.c.Ensure that no air enters the tubing system. Switch to digestion buffer 2 (0.3 mg/mL Collagenase in LPM2) and perfuse 25 mL.a.Maintain flow rate at 6.66 mL/min (dial setting 4).b.Transfer the inlet tubing from digestion buffer 1 to the 50 mL tube containing digestion buffer 2.c.Ensure that no air enters the tubing system. a.Maintain flow rate at 6.66 mL/min (dial setting 4). Maintain flow rate at 6.66 mL/min (dial setting 4). b.Transfer the inlet tubing from digestion buffer 1 to the 50 mL tube containing digestion buffer 2. Transfer the inlet tubing from digestion buffer 1 to the 50 mL tube containing digestion buffer 2. c.Ensure that no air enters the tubing system. Ensure that no air enters the tubing system. 11.Excise the liver and transfer to a 10 cm dish on ice.a.Carefully remove the gallbladder with forceps.b.Gently dissociate the tissue with forceps on ice. Excise the liver and transfer to a 10 cm dish on ice.a.Carefully remove the gallbladder with forceps.b.Gently dissociate the tissue with forceps on ice. a.Carefully remove the gallbladder with forceps. Carefully remove the gallbladder with forceps. b.Gently dissociate the tissue with forceps on ice. Gently dissociate the tissue with forceps on ice. Note: At this stage, the liver should feel soft and partially digested (Figure 1H). Completion of enzymatic digestion and preparation for density gradient separation Timing: 35 min This step completes enzymatic digestion and prepares the cell suspension for density gradient separation while preserving HSC viability. 12.Transfer the perfused liver to a 10 cm dish on ice and add digestion buffer 3.a.Carefully remove the liver from the perfusion setup and place it in the dish on ice.b.Add 10 mL of digestion buffer 3 (0.6 mg/mL Collagenase/Pronase E in LPM2).c.Gently break the liver capsule with sterile tweezers to expose internal tissue (Figure 2A).d.Transfer liver tissue and buffer to a 100 mL flask.e.Rinse the dish with the remaining 10 mL of digestion buffer 3 and transfer to the same flask (final volume: 20 mL). Transfer the perfused liver to a 10 cm dish on ice and add digestion buffer 3.a.Carefully remove the liver from the perfusion setup and place it in the dish on ice.b.Add 10 mL of digestion buffer 3 (0.6 mg/mL Collagenase/Pronase E in LPM2).c.Gently break the liver capsule with sterile tweezers to expose internal tissue (Figure 2A).d.Transfer liver tissue and buffer to a 100 mL flask.e.Rinse the dish with the remaining 10 mL of digestion buffer 3 and transfer to the same flask (final volume: 20 mL). a.Carefully remove the liver from the perfusion setup and place it in the dish on ice. Carefully remove the liver from the perfusion setup and place it in the dish on ice. b.Add 10 mL of digestion buffer 3 (0.6 mg/mL Collagenase/Pronase E in LPM2). Add 10 mL of digestion buffer 3 (0.6 mg/mL Collagenase/Pronase E in LPM2). c.Gently break the liver capsule with sterile tweezers to expose internal tissue (Figure 2A). Gently break the liver capsule with sterile tweezers to expose internal tissue (Figure 2A). d.Transfer liver tissue and buffer to a 100 mL flask. Transfer liver tissue and buffer to a 100 mL flask. e.Rinse the dish with the remaining 10 mL of digestion buffer 3 and transfer to the same flask (final volume: 20 mL). Rinse the dish with the remaining 10 mL of digestion buffer 3 and transfer to the same flask (final volume: 20 mL). Note: Complete transfer of tissue is critical for optimal HSC yield. 13.Add 100 μL of 2 mg/mL DNase I and incubate at 37 °C for 10 min with gentle magnetic stirring (see troubleshooting 3, 4).a.Place the flask on a magnetic stirrer inside a 37 °C incubator and stir gently at 100 rpm (Figure 2B). Add 100 μL of 2 mg/mL DNase I and incubate at 37 °C for 10 min with gentle magnetic stirring (see troubleshooting 3, 4).a.Place the flask on a magnetic stirrer inside a 37 °C incubator and stir gently at 100 rpm (Figure 2B). a.Place the flask on a magnetic stirrer inside a 37 °C incubator and stir gently at 100 rpm (Figure 2B). Place the flask on a magnetic stirrer inside a 37 °C incubator and stir gently at 100 rpm (Figure 2B). CRITICAL: Avoid vigorous agitation, which can induce premature HSC activation. Excessive stress may release activated myofibroblasts into the suspension and simultaneously activate isolated HSCs, compromising purity and quiescence. 14.Add 30 mL of GBSS/B and filter the suspension through a mesh-covered funnel into a 50 mL tube (Figure 2C). Add 30 mL of GBSS/B and filter the suspension through a mesh-covered funnel into a 50 mL tube (Figure 2C). Note: Commercial mesh stockings provide a cost-effective alternative to specialized 70 μm cell strainers. 15.Centrifuge at 600 × g for 10 min at 4 °C (Figure 2D). Centrifuge at 600 × g for 10 min at 4 °C (Figure 2D). 16.Remove the supernatant and add 50 μL of 2 mg/mL DNase I.a.Gently resuspend the pellet by pipetting. Remove the supernatant and add 50 μL of 2 mg/mL DNase I.a.Gently resuspend the pellet by pipetting. a.Gently resuspend the pellet by pipetting. Gently resuspend the pellet by pipetting. CRITICAL: Do not aspirate the supernatant completely. Leave 50–100 μL to prevent cell desiccation. 17.Adjust the suspension to 50 mL with GBSS/B and centrifuge at 600 × g for 10 min at 4 °C. Adjust the suspension to 50 mL with GBSS/B and centrifuge at 600 × g for 10 min at 4 °C. Liver digestion and preparation of cell suspension (A) Gentle mechanical disruption of digested liver tissue using sterile tweezers in a 10 cm dish on ice. (B) Magnetic stirrer placed inside a 37°C incubator for gentle enzymatic digestion with Digestion Buffer 3 at 100 rpm for 10 min. Overview and close-up views are shown. (C) Filtration of the resulting cell suspension through a mesh-covered funnel to remove large tissue fragments. (D) Cell collection by centrifugation at 600 × g for 10 min at 4°C. Nycodenz density-gradient centrifugation and HSC enrichment Timing: 40 min This step separates HSCs from other liver cells based on their lower density due to abundant vitamin A–containing lipid droplets. The optimized 8.8% Nycodenz concentration provides efficient separation while preserving cell viability and TGF-β responsiveness. 18.Remove the supernatant and prepare the Nycodenz suspension.a.Resuspend gently in 10 mL GBSS/B.b.Add 50 μL of 2 mg/mL DNase I to the pellet.c.Add 5.88 mL of 30% Nycodenz stock dropwise while gently mixing.d.Adjust to 20 mL total volume with GBSS/B (final concentration: 8.8% Nycodenz). Remove the supernatant and prepare the Nycodenz suspension.a.Resuspend gently in 10 mL GBSS/B.b.Add 50 μL of 2 mg/mL DNase I to the pellet.c.Add 5.88 mL of 30% Nycodenz stock dropwise while gently mixing.d.Adjust to 20 mL total volume with GBSS/B (final concentration: 8.8% Nycodenz). a.Resuspend gently in 10 mL GBSS/B. Resuspend gently in 10 mL GBSS/B. b.Add 50 μL of 2 mg/mL DNase I to the pellet. Add 50 μL of 2 mg/mL DNase I to the pellet. c.Add 5.88 mL of 30% Nycodenz stock dropwise while gently mixing. Add 5.88 mL of 30% Nycodenz stock dropwise while gently mixing. d.Adjust to 20 mL total volume with GBSS/B (final concentration: 8.8% Nycodenz). Adjust to 20 mL total volume with GBSS/B (final concentration: 8.8% Nycodenz). CRITICAL: The 8.8% Nycodenz concentration was adopted from a previously established protocol3 and provides optimal HSC separation efficiency. Higher concentrations may damage cells, while lower concentrations reduce separation efficiency. 19.Distribute the suspension.a.Aliquot 10 mL into each of two 15 mL centrifuge tubes. Distribute the suspension.a.Aliquot 10 mL into each of two 15 mL centrifuge tubes. a.Aliquot 10 mL into each of two 15 mL centrifuge tubes. Aliquot 10 mL into each of two 15 mL centrifuge tubes. 20.Overlay GBSS/B to form a sharp interface (Figures 3A and 3B) (see troubleshooting 2).a.Slowly add 3 mL GBSS/B onto each tube using either:b.Choose the method that provides best control: Overlay GBSS/B to form a sharp interface (Figures 3A and 3B) (see troubleshooting 2).a.Slowly add 3 mL GBSS/B onto each tube using either:b.Choose the method that provides best control: a.Slowly add 3 mL GBSS/B onto each tube using either: Slowly add 3 mL GBSS/B onto each tube using either: b.Choose the method that provides best control: Choose the method that provides best control: HSC isolation by density-gradient centrifugation (A) Careful overlay of GBSS/B buffer along the tube wall to create a sharp interface without disturbing the gradient. (B) Density-gradient setup showing the distinct 8.8% Nycodenz layer used for HSC separation. (C) Refrigerated centrifuge with swing-bucket rotor for density-gradient centrifugation at 1,500 × g for 22 min at 4°C. The upper panel shows the centrifuge unit, and the lower panel shows the rotor configuration. (D) Post-centrifugation step illustrating removal of the upper lipid layer and selective collection of the HSC-enriched white interface. (E) Final HSC pellet obtained after washing and resuspension. A P1000 pipette set to 1000 μL, dispensing along the tube wall, or a Pasteur pipette held against the tube wall, dispensing slowly. CRITICAL: Prevent mixing of the Nycodenz and GBSS/B layers. A sharp, undisturbed interface is essential for effective separation. 21.Centrifuge the gradient (see troubleshooting 2).a.Spin at 1,500 × g for 22 min at 4 °C (Figure 3C).b.Use slow acceleration and no brake (preferred), or the slowest brake setting available. Centrifuge the gradient (see troubleshooting 2).a.Spin at 1,500 × g for 22 min at 4 °C (Figure 3C).b.Use slow acceleration and no brake (preferred), or the slowest brake setting available. a.Spin at 1,500 × g for 22 min at 4 °C (Figure 3C). Spin at 1,500 × g for 22 min at 4 °C (Figure 3C). b.Use slow acceleration and no brake (preferred), or the slowest brake setting available. Use slow acceleration and no brake (preferred), or the slowest brake setting available. CRITICAL: Avoid abrupt speed changes during acceleration and deceleration to preserve the gradient interface. 22.Remove the lipid layer and collect the HSC-enriched fraction (Figure 3D) (see troubleshooting 2).a.Aspirate the top 1 mL GBSS/B layer to remove floating lipids.b.Carefully collect the next 2 mL, including the white interface layer, with a P1000 or Pasteur pipette.c.Position the pipette tip precisely at the interface and collect all visible white material.d.Transfer collected cells to a fresh 15 mL tube. When processing two mice, pool both interface fractions (approximately 4 mL total) into one tube. Remove the lipid layer and collect the HSC-enriched fraction (Figure 3D) (see troubleshooting 2).a.Aspirate the top 1 mL GBSS/B layer to remove floating lipids.b.Carefully collect the next 2 mL, including the white interface layer, with a P1000 or Pasteur pipette.c.Position the pipette tip precisely at the interface and collect all visible white material.d.Transfer collected cells to a fresh 15 mL tube. When processing two mice, pool both interface fractions (approximately 4 mL total) into one tube. a.Aspirate the top 1 mL GBSS/B layer to remove floating lipids. Aspirate the top 1 mL GBSS/B layer to remove floating lipids. b.Carefully collect the next 2 mL, including the white interface layer, with a P1000 or Pasteur pipette. Carefully collect the next 2 mL, including the white interface layer, with a P1000 or Pasteur pipette. c.Position the pipette tip precisely at the interface and collect all visible white material. Position the pipette tip precisely at the interface and collect all visible white material. d.Transfer collected cells to a fresh 15 mL tube. When processing two mice, pool both interface fractions (approximately 4 mL total) into one tube. Transfer collected cells to a fresh 15 mL tube. When processing two mice, pool both interface fractions (approximately 4 mL total) into one tube. Note: Cells from multiple mice can be pooled at this step for larger-scale preparations. CRITICAL: Avoid aspirating too deeply into the Nycodenz layer, which introduces lymphocytes and dead hepatocytes. Note: The white interface layer contains HSCs, enriched due to their lower density relative to hepatocytes and other liver cells. The lipid layer must be removed to prevent droplet contamination. HSC washing and cell counting Timing: 20 min This step removes residual Nycodenz and prepares cells for culture under conditions. 23.Dilute the suspension with serum-free DMEM to 15 mL and mix gently. Dilute the suspension with serum-free DMEM to 15 mL and mix gently. 24.Centrifuge at 600 × g for 10 min at 4 °C (Figure 3E). Centrifuge at 600 × g for 10 min at 4 °C (Figure 3E). 25.Carefully aspirate the supernatant, leaving 50–100 μL to prevent cell desiccation. Carefully aspirate the supernatant, leaving 50–100 μL to prevent cell desiccation. CRITICAL: Never aspirate completely, as this reduces cell viability. 26.Resuspend the pellet in 1 mL of 0.2% fetal bovine serum (FBS) DMEM by gentle pipetting. Resuspend the pellet in 1 mL of 0.2% fetal bovine serum (FBS) DMEM by gentle pipetting. CRITICAL: Maintain cultures in 0.2% FBS to promote induction of profibrotic genes. In contrast, 10% FBS attenuates basal expression of profibrotic genes and blunts the response to FGF18. 27.Count viable cells using trypan blue exclusion or an automated counter. Count viable cells using trypan blue exclusion or an automated counter. Note: A typical yield is 5.0 × 105 to 1.0 × 106 viable HSCs per mouse, with a purity of 80–90%, as determined by the morphology of the isolated HSCs observed under phase-contrast microscopy with UV illumination (Figure 4). Typical morphology of freshly isolated HSCs Freshly isolated HSCs were examined by phase-contrast microscopy (left) and by UV autofluorescence reflecting vitamin A content (center). The merged image is shown on the right. Scale bar,100 μm. HSC culture preparation Timing: 15 min This step establishes primary HSC cultures for assessing cytokine responses under quiescent conditions. 28.Seed HSCs at 1 × 105 cells per well in 48-well plates.a.Add the appropriate suspension volume to achieve the desired density.b.Supplement culture medium with antibiotics for contamination prevention: 50 μg/ml vancomycin, 50 μg/ml kanamycin, and 10 μg/ml gentamycin. Seed HSCs at 1 × 105 cells per well in 48-well plates.a.Add the appropriate suspension volume to achieve the desired density.b.Supplement culture medium with antibiotics for contamination prevention: 50 μg/ml vancomycin, 50 μg/ml kanamycin, and 10 μg/ml gentamycin. a.Add the appropriate suspension volume to achieve the desired density. Add the appropriate suspension volume to achieve the desired density. b.Supplement culture medium with antibiotics for contamination prevention: 50 μg/ml vancomycin, 50 μg/ml kanamycin, and 10 μg/ml gentamycin. Supplement culture medium with antibiotics for contamination prevention: 50 μg/ml vancomycin, 50 μg/ml kanamycin, and 10 μg/ml gentamycin. 29.Incubate at 37 °C with 5% CO2 in a humidified incubator (see troubleshooting 4). Incubate at 37 °C with 5% CO2 in a humidified incubator (see troubleshooting 4). Note: HSCs begin spontaneous activation after ∼72 h, transitioning from quiescent to activated phenotype. Cells can be used immediately for analysis or maintained for activation studies. For quiescent phenotype assays, harvest within 48 h of seeding. Expected outcomes This protocol enables the isolation of HSCs that retain both morphological and functional features critical for fibrosis research.1,7 Freshly isolated cells displayed a characteristic star-shaped morphology with multiple lipid droplets visible under phase-contrast microscopy (Figure 5A). Gentle mechanical processing is essential: mild agitation preserved the quiescent phenotype, whereas excessive stress induced premature activation, marked by upregulation of α-SMA expression and an increased proportion of α-SMA-positive cells (Figures 5A and 5B). Mechanical processing intensity affects HSC quality (A) Effect of mechanical processing intensity on HSC activation markers. Freshly prepared HSCs were stained with anti-desmin or anti-α-SMA (red) antibodies, with nuclear counterstaining by DAPI (blue). The images were analyzed by confocal microscopy. Scale bar, 100 μm. Representative images from three independent experiments. (B) Increased proportion of α-SMA+ cells under strong mechanical processing. Marker-positive cells was randomly counted and expressed as a percentage of DAPI-positive cells. Data are presented as mean ± SD. The statistical significance was determined by the two-tailed unpaired Student’s t test. ∗p < 0.05; ns, not significant. Figure reprinted and adapted with permission from Seki et al., 2025. Activation status-specific cytokine responsiveness was also observed. Quiescent HSCs responded robustly to TGF-β and FGF18, thereby inducing profibrotic genes (Col1a2, Acta2) and the proliferation marker Ccnd1, respectively (Figure 6A). In contrast, 5-day-cultured HSCs strongly elevated basal Col1a2 and Acta2 expression, but diminished TGF-β responsiveness. Notably, 5-day-cultured HSCs exhibited enhanced FGF18 responsiveness, based on the induction levels of Spp1 (freshly prepared HSCs vs. 5-day-cultured HSCs) (Figures 6A and 6B). Comparison of growth factor responsiveness between primary and immortalized HSCs (A) Gene expression in freshly isolated HSCs. Freshly isolated HSCs were stimulated with FGF18 (100 ng/mL) or TGF-β1 (1 ng/mL) for 24 h. The expression of the indicated genes was quantified by qPCR. Results are mean ± SD with triplicate samples. (B) Gene expression responses in 5-day-cultured HSCs. Freshly prepared HSCs were cultured under serum-starved conditions (0.2 % FBS) without stimulation for 5 days and designated as 5-day-cultured HSCs. These cells were subsequently left untreated or stimulated and analyzed as described in (A). (C) Immortalized HSCs show a complete loss of TGF-β1 responsiveness, but retaining only partial responsiveness to FGF18. Immortalized HSCs were subsequently left untreated or stimulated and analyzed as described in (A). The expression of the indicated genes was quantified by qPCR. Results are mean ± SD with triplicate samples. (D) The human HSC cell line, LX-2, exhibits severely impaired growth factor responsiveness to TGF-β1 and FGF18 stimulation. LX-2 cells were stimulated and analyzed as described in (A). Data are presented as mean ± SD. The statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (A to D). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; ns, not significant. All results are representative of two independent experiments. Figure reprinted and adapted with permission from Seki et al., 2025. Freshly isolated HSCs maintained a quiescent phenotype for 24–48 h in culture before spontaneous activation begins.1 During this period, they expressed desmin with minimal α-SMA, making them suitable for experiments to test TGF-β responsiveness. For studies focusing on the quiescent state, assays should therefore be performed within 48 h of isolation. Overall, this protocol provides access to HSCs with activation status-dependent responsiveness to TGF-β (quiescent) and FGF18 (activated), offering a valuable platform for investigating fibrosis progression, intercellular communication among HSC populations, and potential therapeutic interventions targeting stage-specific signaling pathways. Limitations Despite the protocol’s utility, several limitations should be noted. First, the protocol is optimized for relatively aged female mice (≧24 weeks old) but is not suitable for aged male mice or young mice. Attempts to isolate HSCs from aged males were unsuccessful, likely because lipid accumulation in hepatocytes interferes with Nycodenz gradient separation (data not shown). In addition, isolation from 8-12-week-old mice (average body weight: 20 g) yielded only about 2.0 × 105 cells per animal (data not shown). Retired breeder females are readily available and useful for isolating HSCs from wild-type mice, but obtaining gene-deficient mice at the required age is time-consuming and logistically challenging. Second, because the isolated HSCs are derived from aged animals, we cannot exclude the possibility that aging itself affects cytokine responsiveness, even when cells are freshly prepared. Ideally, gene expression profiles should be compared between young and aged mice; however, the yield of HSCs from young mice is markedly lower, rendering such experiments laborious, although the comparisons remain feasible. Third, the number of HSCs obtained from one mouse is approximately 5.0 × 105 - 1.0 × 106. This yield is sufficient for qPCR but not for biochemical analyses such as Western blotting. Increasing mechanical agitation might improve yield, but as shown in Figure 6A, excessive disruption leads to premature HSC activation, marked by α-SMA expression. To overcome this limitation, larger animals such as rats—originally the species for which the Nycodenz protocol was developed—could be used.8 Alternatively, induced pluripotent stem (iPS) cells may be differentiated into HSC-like cells. Several groups have reported encouraging results using this approach,9,10 but it remains unclear whether iPS-derived HSCs faithfully replicate the gene expression profiles of primary HSCs. Fourth, many laboratories employ immortalized murine or human HSC lines. Our in-house immortalized HSCs retain responsiveness to FGF18 and possibly other cytokines but show no response to TGF-β (Figure 6C). The widely used human HSC line LX-24 exhibits only weak responsiveness to TGF-β and no response to FGF18 (Figure 6D). While immortalized lines are easy to maintain and suitable for repeated experiments, results obtained with these cells must be interpreted with caution. Troubleshooting Problem 1 Poor liver perfusion – The liver appears mottled or retains dark coloration instead of turning uniformly pale yellow (Step 8). Potential solution •Check for needle displacement and secure the needle with a clip immediately after insertion. Check for needle displacement and secure the needle with a clip immediately after insertion. •Verify that the portal vein drainage incision is adequate for outflow. Verify that the portal vein drainage incision is adequate for outflow. •Ensure that the pump flow rate is appropriate (8.33 mL/min for LPM1). Ensure that the pump flow rate is appropriate (8.33 mL/min for LPM1). •Check for air bubbles in the tubing system that may disrupt flow. Check for air bubbles in the tubing system that may disrupt flow. •Confirm that the liver is properly exposed and not compressed by the intestines. Confirm that the liver is properly exposed and not compressed by the intestines. Problem 2 Neither a Nycodenz gradient interface is formed, nor are HSCs enriched at the interface (Steps 20-22). Potential solution •Confirm that the 8.8% Nycodenz concentration is accurate; recalculate and prepare freshly if necessary. Confirm that the 8.8% Nycodenz concentration is accurate; recalculate and prepare freshly if necessary. •Overlay GBSS/B very slowly along the tube wall to avoid mixing. Overlay GBSS/B very slowly along the tube wall to avoid mixing. •Use a centrifuge with slow acceleration and no brake (or the lowest brake setting). Use a centrifuge with slow acceleration and no brake (or the lowest brake setting). •Verify that centrifuge temperature is maintained at 4 °C throughout the run. Verify that centrifuge temperature is maintained at 4 °C throughout the run. •Ensure that the cell suspension is properly resuspended before gradient preparation. Ensure that the cell suspension is properly resuspended before gradient preparation. Problem 3 Low HSC yield with poor cell viability (Steps 13). Potential solution •Shorten digestion time if the tissue appears over-digested. Shorten digestion time if the tissue appears over-digested. •Reduce the magnetic stirring speed to 100 rpm to minimize mechanical stress. Reduce the magnetic stirring speed to 100 rpm to minimize mechanical stress. •Maintain all solutions at the appropriate temperature (37 °C for enzyme digestion, 4 °C for washes). Maintain all solutions at the appropriate temperature (37 °C for enzyme digestion, 4 °C for washes). •Avoid complete aspiration of the supernatant during washing steps. Avoid complete aspiration of the supernatant during washing steps. •Use freshly prepared enzyme solutions; do not store digestion buffers. Use freshly prepared enzyme solutions; do not store digestion buffers. •Process samples quickly and keep cells on ice whenever possible. Process samples quickly and keep cells on ice whenever possible. Problem 4 HSCs undergo premature activation and fail to respond to TGF-β1 (Steps 13, 28-29). Potential solution •Use gentler mechanical processing during tissue dissociation. Use gentler mechanical processing during tissue dissociation. •Reduce magnetic stirring speed (set dial to a maximum of 1). Reduce magnetic stirring speed (set dial to a maximum of 1). •Minimize the time between isolation and culture plating. Minimize the time between isolation and culture plating. •Maintain low-serum conditions (0.2% FBS) throughout culture. Maintain low-serum conditions (0.2% FBS) throughout culture. •Perform TGF-β1 stimulation experiments within 48 h of isolation. Perform TGF-β1 stimulation experiments within 48 h of isolation. •Avoid vigorous pipetting during cell resuspension. Avoid vigorous pipetting during cell resuspension. Problem 5 Inconsistent results between preparations. Potential solution •Standardize the timing between mouse sacrifice and initiation of perfusion. Standardize the timing between mouse sacrifice and initiation of perfusion. •Use retired breeder females consistently to ensure age standardization. Use retired breeder females consistently to ensure age standardization. •Prepare all enzyme solutions freshly for each isolation. Prepare all enzyme solutions freshly for each isolation. •Maintain strict temperature control throughout the procedure. Maintain strict temperature control throughout the procedure. •Apply a reproducible and standardized gradient overlaying technique. Apply a reproducible and standardized gradient overlaying technique. Resource availability Lead contact Further information and requests for resources and reagents should be addressed to and will be fulfilled by the lead contact, Hiroyasu Nakano (hiroyasu.nakano@med.toho-u.ac.jp). Technical contact Technical questions regarding the execution of this protocol should be directed to and will be answered by the technical contact, Takao Seki (takao.seki@med.toho-u.ac.jp). Materials availability This protocol did not generate new unique reagents. Data and code availability This protocol did not generate any original datasets or custom code. Acknowledgments This work was supported in part by Grants-in-Aid for Scientific Research (B) (20H03475 and 23H02707 to H.N.) and Scientific Research (C) (17K08994 and 20K11589 to Y.T. and 25K10306 to T.S.) from the Japan Society for the Promotion of Science (JSPS); the Japan Agency for Medical Research and Development through AMED-CREST (23gm1210002 to H.N.) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; the Princess Takamatsu Cancer Research Fund (to H.N.); the Takeda Science Foundation (to H.N.); and the Center for Diversity and Inclusion of Toho University’s Collaborative Research Enhancement Support (to T.S.). The graphical abstract was created using BioRender. Seki, T. (2025) https://BioRender.com/nwby1b8. Author contributions T.S. and H.N. designed the study and interpreted the results. T.S. and S.K.-S. performed and analyzed most of the experiments. Y.T., K.F., Y.N., K.I., and K.O. supervised the experiments. T.S. and H.N. wrote the manuscript with constructive input from all authors. Declaration of interests The authors declare no competing interests. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.xpro.2025.104266. Contributor Information Takao Seki, Email: takao.seki@med.toho-u.ac.jp. Hiroyasu Nakano, Email: hiroyasu.nakano@med.toho-u.ac.jp. Supplemental information Data S1. Source data files References Associated Data Supplementary Materials Data S1. Source data files Data Availability Statement This protocol did not generate any original datasets or custom code.